Jana Barinoff

Jana Barinoff

Auto-generated profile, based on publicly available information

Jana Barinoff

Charité-Universitätsmedizin Berlin

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2015 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
AKA. Kümmel
A. Kümmel
SKS. Kümmel
S. Kümmel
JBJ. Barinoff
J. Barinoff
FHFlorian Dr. Heitz
Florian Dr. Heitz
JHJ. Holtschmidt
J. Holtschmidt
BABeyhan Ataseven
Beyhan Ataseven
Aim: The risk of recurrence in breast cancer depends on factors such as treatment but also on the intrinsic subtype. We analyzed the risk factors for local, loco-regional and systemic recurrence, evaluated the differences and analyzed the risk of recurrence for different molecular subtypes. Material and Methods: A total of 3054 breast cancer patients who underwent surgery followed by adjuvant treatment at HSK hospital or Essen Mitte Hospital between 1998 and 2011 were analyzed. Based on immunohistochemical parameters, cancers were divided into the following subgroups: luminal A, luminal B (HER2-), luminal B (HER2+), HER2+ and TNBC (triple negative breast cancer). Results: 67 % of tumors were classified as luminal A, 13 % as luminal B (HER2-), 6 % as luminal B (HER2+), 3 % as HER2+ and 11 % as TNBC. After a median follow-up time of 6.6 years there were 100 local (3.3 %), 32 loco-regional (1 %) and 248 distant recurrences (8 %). Five-year recurrence-free survival for the overall patient collective was 92 %. On multivariate analysis, positive nodal status, TNBC subtype and absence of radiation therapy were found to be independent risk factors for all forms of recurrence. Age < 50 years, tumor size, luminal B (HER2-) subtype and breast-conserving therapy were additional risk factors for local recurrence. Compared to the luminal A subtype, the risk of systemic recurrence was higher for all other subtypes; additional risk factors for systemic recurrence were lymphatic invasion, absence of systemic therapy and mastectomy. Conclusion: Overall, the risk of local and loco-regional recurrence was low. In addition to nodal status, subgroup classification was found to be an important factor affecting the risk of recurrence. Fragestellung: Das Rezidivrisiko beim Mammakarzinom wird durch therapeutische Faktoren, aber auch durch den intrinsischen Subtyp beeinflusst. Diese Arbeit analysiert Risikofaktoren für lokales und lokoregionäres Rezidiv sowie systemische Rezidive, die Evaluation eventuell vorhandener Unterschiede sowie die Analyse des Rezidivrisikos in verschiedenen molekularen Subtypen. Material/Methoden: Analysiert wurden 3054 Patientinnen mit Mammakarzinom, die an den HSK-Wiesbaden und Kliniken Essen-Mitte zwischen 1998–2011 operiert und adjuvant behandelt wurden. Anhand immunhistochemischer Parameter erfolgte die Subgruppierung in Luminal A, Luminal B/HER2−, Luminal B/HER2+, HER2+ und TNBC. Ergebnisse: 67 % der Tumoren wurden als Luminal A, 13 % Luminal B/HER2−, 6 % Luminal B/HER2 +, 3 % HER2+ und 11 % TNBC kategorisiert. Nach einer medianen Nachbeobachtung von 6,6 Jahren traten 100 lokale (3,3 %), 32 lokoregionäre (1 %) Rezidive und 248 Fernmetastasen (8 %) auf. Das metastasenfreie 5-Jahres-Überleben für das Gesamtkollektiv betrug 92 %. In den multivariaten Analysen waren ein positiver Nodalstatus, der TNBC-Subtyp und die nicht durchgeführte Radiotherapie unabhängige Risikofaktoren für alle Rezidivformen. Für das Lokalrezidiv waren zudem Alter < 50 Jahre, Tumorgröße, Luminal B/HER2− und die brusterhaltende Therapie unabhängige Risikofaktoren. Das Risiko für systemische Rezidive war verglichen mit dem Luminal-A-Subtyp in allen weiteren Subtypen erhöht, neben dem Nachweis einer Lymphgefäßinvasion, nicht erfolgter Systemtherapie und Mastektomie. Schlussfolgerung: Insgesamt zeigt sich ein niedriges Risiko für lokale und lokoregionäre Rezidive. Neben dem Nodalstatus ist vor allem die Subgruppenklassifikation ausschlaggebend.

15 October 2018 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
KJKorinna Jöhrens
Korinna Jöhrens
LLLea Lazzerini
Lea Lazzerini
JBJana Barinoff
Jana Barinoff
JSJalid Sehouli
Jalid Sehouli
GCGuenter Cichon
Guenter Cichon

1 August 2011
Verified
Journal Article
Closed access
SLSolveig Landt
Solveig Landt
KMKonstanze Mordelt
Konstanze Mordelt
ISIlka Schwidde
Ilka Schwidde
JBJana Barinoff
Jana Barinoff
SKSusanne Korlach
Susanne Korlach
SKSherko Kümmel
Sherko Kümmel



20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJana Barinoff
Jana Barinoff
JSJalid Sehouli
Jalid Sehouli
BHBernd Holleczek
Bernd Holleczek
E17031 Background: Incidence of vulvar cancer in Germany is increasing. Gynecological oncologists reported to observe increasing numbers of women presenting with small tumors. The aim of the presented study is to validate this observation on a population level and to extend available incidence data. Methods: Data from the population-based Saarland Cancer Registry (CR) were used and included 1,136 female patients diagnosed with invasive vulvar cancer (ICD-10 code: C51) between 1974 and 2013. Multiple imputation methodology was used to overcome loss of precision and potential bias. Incidence trends were investigated with regard to patient and tumor characteristics. Results: During the study period, the age standardized rate of incidence increased from 1.6 to 7.9 cases per 100,000 women per year (+390%). Since 1989, the incidence of squamous cell carcinoma increased from 1.7 to 7.1 (+320%), whereas no increase was observed in other morphologic types. Simultaneously, the incidence of small vulvar tumors <= 2 cm (T1) increased from 0.8 in 1989-93 to 6.6 in 2009-13 (the proportion of T1 tumors increased from 34% to 79%, respectively). Patients aged >= 75 years suffered from more advanced disease at the time of diagnosis. Conclusions: The detailed analyses revealed that the observed increase in vulvar cancer in the past 15 years mainly resulted from newly incident squamous cell carcinomas. Furthermore, the analyses showed an almost exclusive increase of T1 tumors. An increase in vulvar cancer incidence as shown for Germany could not be observed for any other European country.